Vanda Pharmaceuticals (FRA:VM4) Interest Expense: €0.0 Mil (TTM As of Mar. 2026)


FRA:VM4 Vanda Pharmaceuticals Inc FRA:VM4
75 GF Score
Price €5.10
GF Value €4.70
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Interest Expense?

Vanda Pharmaceuticals FRA:VM4 +4.94% 75 Interest Expense is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:VM4 with a GF Score™ of 75/100 and a GF Value™ of €4.70 (Fairly Valued). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Vanda Pharmaceuticals's interest expense for the three months ended in Mar. 2026 was € 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Vanda Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was € -43.4 Mil. Vanda Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was € 0.0 Mil. GuruFocus does not calculate Vanda Pharmaceuticals's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vanda Pharmaceuticals  (FRA:VM4) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vanda Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was €0.0 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-43.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €6.1 Mil.

Vanda Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Vanda Pharmaceuticals's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Vanda Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

Vanda Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Interest Expense Chart

Vanda Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vanda Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:VM4
75GF Score
Vanda Pharmaceuticals Inc FRA:VM4
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanda Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €0.0 Mil mean?
Vanda Pharmaceuticals (FRA:VM4) has a Interest Expense of €0.0 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Vanda Pharmaceuticals and its competitors.
Is Vanda Pharmaceuticals' Interest Expense too high?
Vanda Pharmaceuticals' current Interest Expense is €0.0 Mil. Overall, Vanda Pharmaceuticals has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Interest Expense compare to FBRX and ARTV?
Vanda Pharmaceuticals' Interest Expense of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Vanda Pharmaceuticals and its competitors. Vanda Pharmaceuticals's current Interest Expense is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (FRA:VM4) is currently considered Fairly Valued. The stock's GF Value™ is €4.70, compared to a current price of €5.10 — trading 8.5% above its estimated fair value. The current Interest Expense is €0.0 Mil. Vanda Pharmaceuticals' overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Vanda Pharmaceuticals (FRA:VM4), the current Interest Expense is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanda Pharmaceuticals (FRA:VM4) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued. The current stock price of €5.10 is trading 8.5% above its estimated GF Value™ of €4.70. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:VM4:

  • Interest Expense: €0.0 Mil
  • GF Value™: €4.70 vs. price of €5.10 (8.5% above fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the FRA:VM4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanda Pharmaceuticals Business Description

Other Exchanges VNDA:USA0LKB:UKVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
75GF Score

Get the complete analysis for FRA:VM4

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.10
Price
€4.70
GF Value